Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 13/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 3/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504227 | 1.00 | NQO2 (0.57) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL398449 | 0.90 | NQO2 (0.48) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL3506133 | 0.89 | NQO2 (0.47) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Maleic Acid SCHEMBL3508868 | 0.88 | NQO2 (0.52) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| Pafuramidine SCHEMBL29711459 | 0.88 | NQO2 (0.52) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL5489885 | 0.86 | PRMT1 (0.59) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL5493324 | 0.86 | NQO2 (0.45) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL6004202 | 0.81 | NQO2 (0.51) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL4952348 | 0.80 | ALDH1A1 (0.44) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL5485793 | 0.79 | NQO2 (0.53) | NQO2PRMT1ALDH1A1TOP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| US-20070276020-A1 | Dicationic Compounds For Activity Against Trichomonas Vaginalis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | claimed |
| WO-2005086754-A2 | DICATIONIC COMPOUNDS FOR ACTIVITY AGAINST TRICHOMONAS VAGINALIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2026090318-A2 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY-Tech Labs, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY TECH LABS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250368679-A1 | FORMATION OF AMIDINES | VANVELLER BRETT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | disclosed |
| WO-2005086754-A2 | DICATIONIC COMPOUNDS FOR ACTIVITY AGAINST TRICHOMONAS VAGINALIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086808-A2 | NOVEL DICATIONIC IMIDAZO[1,2-a]PYRIDINES AND 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2a]PYRIDINES AS ANTIPROTOZOAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1565457-A2 | PROCESS FOR SYNTHESIS BIS-ARYL DIAMIDOXIME COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040127721-A1 | Process for the synthesis of bis-aryl diamidoxime compounds | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-07-01 | — | — | US | disclosed |
| WO-2004051217-A2 | PROCESS FOR SYNTHESIS BIS-ARYL DIAMIDOXIME COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | LIPA, LIPC, ACACA | NQO2 3127/4885PRMT1 4613/4885ALDH1A1 1598/4885 |
| US-20250368679-A1 | FORMATION OF AMIDINES | H1-4, H1-2, H1-3 | NQO2 640/4885PRMT1 50/4885ALDH1A1 3396/4885 |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | NQO2 1536/4885PRMT1 1379/4885ALDH1A1 463/4885 |
| US-20040127721-A1 | Process for the synthesis of bis-aryl diamidoxime compounds | DDT, DAO, DDO | NQO2 339/4885PRMT1 3200/4885ALDH1A1 586/4885 |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | NQO2 1536/4885PRMT1 1379/4885ALDH1A1 463/4885 |
| US-20070276020-A1 | Dicationic Compounds For Activity Against Trichomonas Vaginalis | CASP12, DLD, HDAC5 | NQO2 1046/4885PRMT1 1577/4885ALDH1A1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.